Please login to the form below

Not currently logged in
Email:
Password:

FDA issues haloperidol cardiovascular prescribing update

The FDA has updated the warnings section of the prescribing information for J&J's Haldol treatment for psychosis

The FDA has updated the warnings section of the prescribing information for Johnson & Johnson's (J&J) Haldol (haloperidol) treatment for psychosis.

The label has been revised to include a new cardiovascular subsection regarding cases of sudden death, QT prolongation and Torsades de Pointes (TdP) in patients treated with haloperidol, especially when given intravenously, or at doses higher than recommended. Both cases refer to different types of ventricular tachycardia, where heart beat speed increases.

Although injectable haloperidol is only approved by the FDA for intramuscular injection, there is strong evidence that the intravenous administration of haloperidol is a relatively common off-label clinical practice.

There have been at least 28 case reports of QT prolongation and TdP, some with fatal outcome in the context of off-label intravenous haloperidol. Healthcare professionals should consider this new risk information when making individual treatment decisions for their patients.

According to Reuters, J&J's stock fell USD 0.26 to rest at USD 62.94 in 17 September afternoon trading on the New York Stock Exchange composite.

Atypical antipsychotics have replaced Haldol and posted sales of USD 11.5bn in 2006, according to IMS Health data. J&J does not routinely release Haldol sales figures.

18th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics